Table: Daito - 6-MTH group results
Jan 11 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Nov 30, 2018 Nov 30, 2017 May 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 20.15 20.45 40.80
(-1.5 pct) (+6.4 pct) (+2.3 pct)
Operating 2.33 2.27 4.30
(+2.7 pct) (+6.5 pct) (+3.3 pct)
Recurring 2.37 2.30 4.35
(+2.8 pct) (+10.6 pct) (+2.5 pct)
Net 1.67 1.59 3.10
(+5.5 pct) (+11.5 pct) (+1.9 pct)
EPS 133.74 yen 126.82 yen 247.72 yen
Ann Div 33.00 yen 36.00 yen
-Q2 div 18.00 yen 15.00 yen
-Q4 div 18.00 yen 18.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results